企業プロフィール
Aethlon Medical 株価・ニュース・カタリスト
- ティッカー:
- AEMD
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
2.94 USD (+3.71%)
終値
最終更新: 2026年8月17日
3.47M USD
時価総額
株価変動の要因
As of Aug 17, 2026, AEMD closed up 3.71% at $2.94. No new same-company headline was identified in the current news window.
企業概要
Clinical-Stage Medical Device Company
Aethlon Medical is developing the Hemopurifier, an extracorporeal device designed to remove enveloped viruses and tumor-derived extracellular vesicles from blood. The company is pursuing applications in oncology, life-threatening viral infections, and other inflammation-associated diseases.
Hemopurifier Mechanism
The Hemopurifier combines plasma separation, size exclusion, and affinity binding using a plant-derived lectin resin that targets mannose-rich structures on extracellular vesicles and viral surfaces. Tumor-derived EVs are believed to contribute to metastasis and resistance to immunotherapy and chemotherapy.
Oncology and Infectious Disease Platform
The same extracorporeal filtration approach may be applicable across diseases involving circulating pathogenic particles. Aethlon is currently prioritizing tumor-derived EV removal in oncology while retaining potential applications in severe enveloped viral infections.
Oncology Development Path
Aethlon is conducting an Australian study in patients with solid tumors whose disease is stable or progressing on anti-PD-1 therapy. The first two dose cohorts have been completed, and treatment has begun in the third and final cohort.
今後のカタリスト
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。